Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.31 |
| ▸ | FBP1 | P09467 | 1/20 | 0.31 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6638172 | 0.83 | TAAR1 (0.38) | ADRA1D | |
| SCHEMBL3026911 | 0.78 | ADRA1D (0.37) | ADRA1DPARP1BACE1KEAP1 | |
| SCHEMBL11421425 | 0.76 | GABRA1 (0.40) | POLBKEAP1PDE7AGABRA1GABRB2 | |
| SCHEMBL956562 | 0.76 | ALDH1A1 (0.43) | ADRA1D | |
| SCHEMBL15061193 | 0.75 | ADRA1D (0.33) | ADRA1DPOLBBACE1 | |
| SCHEMBL266174 | 0.75 | — | — | |
| SCHEMBL23877337 | 0.74 | KEAP1 (0.31) | KEAP1PDE7AGABRA1GABRB2 | |
| SCHEMBL9036511 | 0.74 | GABRA1 (0.39) | POLBKEAP1FBP1PDE7AHDAC3 | |
| SCHEMBL22863972 | 0.74 | SLC6A3 (0.41) | KEAP1FBP1PDE7AGABRA1GABRB2 | |
| SCHEMBL12702042 | 0.74 | FBP1 (0.32) | KEAP1FBP1PDE7AGABRA1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025044926-A1 | THIENYLSULFONYL CARBAMATES AS AT2R AGONISTS | 武汉人福创新药物研发中心有限公司 | 2025-03-06 | — | — | WO | disclosed |
| CN-119504723-A | Thiophene sulfonyl carbamates as AT2R agonists | 武汉人福创新药物研发中心有限公司 | 2025-02-25 | — | — | CN | disclosed |
| US-8318751-B2 | Pyrimidinone derivatives and methods of use thereof | MERCK SHARP & DOHME CORP. (US) | 2012-11-27 | — | — | US | disclosed |
| US-20110178092-A1 | HIV-1 Protease Inhibitors | UNIVERSITY OF MARYLAND, COLLEGE PARK | 2011-07-21 | — | — | US | disclosed |
| US-20110178092-A1 | HIV-1 Protease Inhibitors | UNIVERSITY OF MARYLAND, COLLEGE PARK | 2011-07-21 | — | — | US | disclosed |
| US-20100113487-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113487-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, GPR180, GPR17 | ADRA1D 209/4885POLB 2241/4885PARP1 971/4885 |
| US-20110178092-A1 | HIV-1 Protease Inhibitors | SERPINB1, PRSS1, TMPRSS4 | ADRA1D 4478/4885POLB 1302/4885PARP1 475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.